‘Jumping Genes’ Support Immune Cells in Tissue
23.07.2024Researchers at the Leibniz Institute for Immunotherapy (LIT) describe a new type of regulation of immune cells by so-called ‘jumping genes.’
Category: 1
Leibniz Institute for Immunotherapy (LIT) receives Total E-Quality award for equal opportunity strategy
18.07.2024Due to exemplary actions in the field of equal opportunity-oriented personnel and organizational policies, Leibniz Institute for Immunotherapy is awarded the TOTAL E-QUALITY award for the second time, which is valid for the years 2024 to 2026.
International LIT Symposium “Synthetic Immunology / Synthetic Biology” in Regensburg
02.07.2024More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg.
CAR T-REX Consortium brings together experts in Cell and Gene therapies for General Assembly at CiQUS, Universidade de Santiago de Compostela (Spain)
25.06.2024Cell and Gene therapy experts from the international consortium ‘CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment’ (CAR T-REX) gathered on the 28 and 29 May for a General Assembly at CiQUS, Universidade de Santiago de Compostela.
Bringing research results of gene and cell therapy to the clinic faster
20.06.2024Leibniz scientists significantly involved in national strategy for gene and cell-based therapies.
€2.6 Million Funding Boosts Ground-breaking CAR T Cell Therapy Study in Advanced Lymphomas
07.05.2024Luca Gattinoni and Matthias Edinger from the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) have received a 2.6 million euro grant from the German Cancer Aid. The funding will support an innovative clinical study using stem-like CAR T cells to treat patients with advanced lymphomas.
International LIT Symposium 2024 “Synthetic Immunology / Synthetic Biology”
15.03.2024The International LIT Symposium takes place June 26th – 27th, 2024 in Regensburg, Germany.
LIT Postdoctoral Scientist Dr. Jeremy Baldwin receives Fellowship by Joachim Herz Foundation
08.02.2024Dr. Jeremy Baldwin, Postdoctoral Scientist in the Functional Immune Cell Modulation Division of the LIT, received an Add-on Fellowships for Interdisciplinary Life Science of 12.500€ by the Joachim Herz Foundation for his research project on metabolically reprogramming CD8+ T cells for cancer immunotherapy applications.
Members of the German Bundestag visit the LIT
24.01.2024Peter Aumer and Katrin Staffler, members of the German Bundestag, visited the LIT on January 24, 2024.
Killer T Cells Support Tissue Regeneration
16.01.2024Researchers at the Leibniz Institute for Immunotherapy (LIT) have demonstrated that killer T cells of the immune system not only eliminate pathologically altered cells, but also promote the subsequent tissue wound healing process.